Kaneka Strengthens mRNA Production with Expansion of GMP Manufacturing Capacity at Eurogentec S.A.

Kaneka Corporation is taking the initiative to expand its GMP manufacturing capacity for mRNA with a capital investment of 2 billion JPY. By the end of 2023, Kaneka Eurogentec S.A., a wholly owned group company in Europe, is expected to have a production capacity that is five times higher than its current capacity. Kaneka Eurogentec S.A. will become a leading CDMO in the biopharmaceutical industry, responding to the increasing global demand for mRNA.

The revolutionary mRNA technology, quickly employed in vaccine production for COVID-19, is expected to revolutionize the way we tackle not only infectious diseases, but also genetic diseases, cancer and more. With pharmaceutical companies across the globe ramping up their biopharmaceutical pipelines, there is a rapidly increasing demand for GMP manufacturing of mRNA. This promises to bring us a brighter and healthier future.

Kaneka Eurogentec S.A. is a leading CDMO for biopharmaceuticals, having been inspected and approved by the US FDA*4 and possessing world-class technology for producing plasmid DNA*5. With over 25 years of GMP manufacturing experience, they provide a wide range of drug substances, from plasmid DNA and recombinant proteins to oligonucleotide*6, to pharmaceutical companies around the globe. Moreover, since 2020, Kaneka Eurogentec S.A. has been offering GMP manufacturing services for mRNA, enabling them to further expand their CDMO business.

Kaneka is committed to making a global impact on health care, pushing the boundaries of biopharmaceuticals to provide solutions to health issues around the world. With a focus on health care, Kaneka is striving to create innovative solutions to improve the quality of life and well-being of people everywhere.

Ensuring consistent production and control of products according to quality standards is essential, and Good Manufacturing Practice (GMP) is the system that makes it happen. GMP sets the bar for quality assurance, ensuring products are produced with the highest level of safety, efficacy, and consistency.

mRNA is an incredibly powerful molecule, transcribed from DNA to provide genetic information for protein synthesis. This incredible molecule has the potential to be used for revolutionary vaccines and therapeutics, revolutionizing the healthcare industry and opening up a new world of possibilities for medical science.

Having a reliable Contract Development and Manufacturing Organization (CDMO) is key to a successful business. A CDMO provides the essential services necessary for the development, manufacture, and commercialization of drug products. Without the right organization, a business won’t be able to quickly and efficiently produce the necessary products to stay competitive. Finding the right CDMO is essential to a successful business.

The Food and Drug Administration (FDA) is a US governmental agency tasked with ensuring the safety and efficacy of products used by consumers in their daily lives. From pharmaceuticals, cosmetics, medical devices, veterinary drugs and toys, the FDA works diligently to approve and supervise the use and sale of these products in the market. By doing so, they help to protect and empower consumers so they can use these products with confidence.

Plasmid DNA can be found in the cells of bacteria like E. coli and yeast, and is a remarkable circle of genetic information that is passed from one generation to the next. These small, circular molecules are known for their incredible ability to store and transfer genetic material, making them invaluable tools for scientists and researchers around the world.

Biopharmaceuticals such as therapeutic proteins, genetic medicines and even vaccines are being produced using conventional processes. This powerful technology has revolutionized the way medical treatments are being developed, allowing for faster and more efficient production of treatments with fewer side effects.

Oligonucleotides are short polymeric sequences of nucleotides composed of both RNA and DNA, and are being used as a revolutionary drug substance for nucleic acid therapeutics. Their small size and ability to interact with specific molecules makes them a powerful tool for targeting and treating a variety of diseases and illnesses. With the potential to revolutionize the healthcare industry, oligonucleotides are sure to be a game changer in the near future.

Leave a Comment